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Abstract        
 G protein-coupled receptors (GPCRs) constitute the largest family of 
membrane receptors. Essential for the control of several physiologic and 
pathophysiologic processes, such cancer, hypertension, abnormal bone 
development, and others, GPCRs are one of the most studied families of receptors. 
The number of drugs targeting these receptors has been increasing, counting with 
more than 475 FDA approved drugs. 
In this work we focused in four GPCRs: Cannabinoid Receptor 1 (CB1) and 2 
(CB2), two cannabinoid receptors, G protein coupled receptor 18 (GPR18) and 55 
(GPR55), two orphan receptors. CB1 and CB2 belong to the GPCR family class A. 
CB1 is highly expressed in the central nervous system (CNS), while CB2 is abundant 
in peripheral organs with immune function. GPR55 belongs to the GPCR family class 
A, and it is suggested as a therapeutic target in obesity, diabetes, osteoporosis and 
cancer. GPR18 also is a class A GPCR, and may be a therapeutic target in 
inflammatory diseases, cancer, and intraocular high pressure.  
 Therefore, the aim of this study was to identify and evaluate pharmacologically 
surrogate ligands of these cannabinoid receptors. 
Previous studies from our lab also identified some compounds, from the in-
house library, that were able to modulate these receptors’ activity. Based on these 
molecular structures, we screened the agonist and antagonist effect of these new 
compounds, from our in-house library. For that initial screening was performed, 
followed by selectivity and potency studies, using the β-arrestin recruitment assay, 
radioligand binding assay and cAMP accumulation assay. For GPR18, two series of 
compounds were tested (compound library 1 and 2), while for CB2 only one series of 
compounds (compound library 3) were tested. Selectivity studies were performed 
using with GPR55 and CB1, respectively.  
 Our results identified one promising compound for GPR18 (EC50(compound 
56)=0.0302±0.004 μM) and another one for CB2 (Ki(compound 76)=0.339±0.061 
µM).  
In the future, more studies need to be done to understand how these 
compounds modulate these receptors’ activity and to optimize their activity, with the 
goal of developing new molecules that could be used as a therapeutic approach to 














Os recetores acoplados à proteína G (GPCRs) constituem a maior família de 
recetores membranares, sendo essenciais no controlo de processos fisiológicos e 
patofisiológicos, como cancro, hipertensão, entre outros.  O número de fármacos 
direcionados para estes recetores tem vindo a aumentar, contando com mais de 475 
aprovados pela FDA. 
 Neste estudo focámo-nos em quatro recetores: Recetor Canabinoide 1 (CB1) 
e 2 (CB2) e recetor acoplado à proteína G 18 (GPR18) e 55 (GPR55), dois recetores 
órfãos. CB1 e CB2 pertencem à classe A da família de GPCRs. A expressão de CB1 
é elevada no sistema nervoso central, enquanto que CB2 é abundante em órgãos 
periféricos com função imunitária. GPR55 pertence à classe A da família de GPCRs, 
sendo sugerido como alvo terapêutico na diabetes, obesidade, osteoporose e 
cancro. GPR18 pertence também à classe A e poderá ser alvo em terapias para 
cancro e doenças inflamatórias.  
 O objetivo deste estudo consistiu na identificação e avaliação farmacológica 
de ligandos destes recetores. 
 Estudos anteriores do nosso laboratório identificaram alguns compostos, de 
uma biblioteca de compostos in-house, capazes de modular a atividade destes 
recetores. Tendo por base a estrutura molecular destes, fizemos o screening do 
efeito antagonista e agonista destes novos compostos, pertencentes também à 
nossa biblioteca. Seguidamente ao screening inicial, foram realizados estudos de 
seletividade e potência, recorrendo a ensaios de recrutamento de β-arrestina, 
ligação de radioligandos e acumulação de cAMP. Para o GPR18 foram testadas 
duas séries de compostos (biblioteca de compostos 1 e 2), enquanto que para o 
CB2 foi testada apenas uma série de compostos (biblioteca de compostos 3). Os 
estudos de seletividade foram realizados com GPR55 e CB1, respetivamente. 
 Os nossos resultados identificaram um composto promissor para GPR18 
(EC50(composto56)=0.0302±0.004 μM) e um para CB2 
(Ki(composto76)=0.339±0.061 µM). No entanto, mais testes devem ser executados, 
de forma a clarificar se estes compostos conseguem efetivamente modular a 
atividade destes recetores. 
Futuramente, será necessária a realização de novos estudos, permitindo 
compreender como estes compostos modulam a atividade destes recetores e 
otimizar a mesma, com objetivo de desenvolver novas moléculas a serem usadas 
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1. G Protein-Coupled Receptors (GPCRs) 
G protein-coupled receptors (GPCRs) comprise about 1000 of distinct 
receptors, being the most common and the largest family of membrane receptors. 
These receptors are encoded by more than 800 genes in the human genome, 
comprising about 1% to 5% of the entire vertebrate’s genome. GPCRs recognize 
several ligands including neurotransmitters, small molecules, hormones, peptides, 
biogenic amines, amino acids, nucleosides, elemental ions, lipids and photons of 
light (1,2).  
More than 140 GPCRs are considered orphan receptors, since they have a 
similar structure to others identified receptors but they have unknown endogenous 
selective and exclusive ligand(s) (1,3). 
When GPCRs are overactive or inactive, they can be associate to several 
diseases and syndromes, such as abnormal bone development, night blindness, 
stroke, cancer, thyroid dysfunction, congenital bowel obstruction, hypertension, 
congestive heart failure and neonatal hyperparathyroidism (2). 
The superfamily of GPCRs can be divided into six principal families. Class A 
or 1, the rhodopsin receptor family, includes around 85% of GPCRs and this class 
responds to exogenous and endogenous ligands, and can be divided in further three 
subclasses (I, II and III) according to the type of ligands. Subclass I include ligands 
like neurotransmitters and light photons, subclass II includes receptors for peptides 
and subclass III for glycoprotein hormones. Class B or 2, the secretin receptor family, 
respond to large proteins and peptide hormones, such as gastrointestinal hormones, 
calcitonin, parathyroid hormone, growth hormone-releasing factors, and others. Class 
C or 3,  includes metabotropic glutamate receptors (mGluRs), gamma-aminobutyric 
acid (GABAB) receptors, pheromone receptors, Ca2+-sensing receptors (CaSRs) of 
the brain, parathyroid and kidney, sweet and amino acid taste receptors (TAS1R) 
and odorant receptors in fish. Class D or 4, corresponds to the fungal mating 
pheromone receptors, and Class E or 5, cyclic adenosine monophosphate (cAMP) 
receptors, are involved in the developmental control. Finally, F or 6 correspond to 
frizzled/smoothened, receptors that are involved in embryonic development and other 
cellular and physiologic processes. The classes D and E are not found in vertebrates 
(1,2).  
GPCRs are composed by an extracellular (EC) domain, being the most 
variable region between receptors, contrasting with the transmembrane region and 
the ligand-binding pocket, and, finally, by the intracellular (IC) domain (since its 













The transduction of the signal across the cell membrane is made by the 
transmembrane domain. This domain has a common structure between the different 
GPCR’s classes, and it is composed by a bundle of seven α-helices, inserted in the 
cell membrane (termed TM1 through TM7), connected by three intracellular and 
three extracellular loops (termed ICL1 through ICL3 and ECL1 through ECL3, 
respectively). It is also important for the mediation of interactions of the receptor and 
the intracellular components, including GTP binding proteins (G-proteins) and 
arrestins  The rearrangement of the transmembrane helices plays a crucial role in the 
transmission of the signal to the interior of the cell (2,3,4). 
The GPCR’s ability to change between different conformations, allows these 
receptors, to detect the presence of several molecules, to transmit a signal through 
the cell membrane and to initiate a variety of intracellular signalling cascades in 
response to ligand biding. Thus, the study of the structural dynamics of GPCRs is an 
important instrument to the design of targeted drugs (4). 
Different ligands binding induces multiple conformational states, with different 
abilities to recruit intracellular binding partners, which can lead to the activation of 
distinct signalling pathways. Generally, binding of a ligand to a GPCR alter the 
fraction of time that the receptor remains in a certain conformational state (4). 
GPCRs have a complex response process. The majority of these receptors 
tend to have baseline activity, even in the absence of any external stimulus. The 
response of the receptor can be different according to the type of ligand (Fig.2A). A 
full agonist induces maximal receptor activity by stabilizing an active conformation, 
while a partial agonist just induces a partial activity of the receptor and has affinity to 
the active and inactive conformations. An inverse agonist differs from a antagonist (or 
neutral agonist) because, while an antagonist prevent others ligands from binding 
and activating the receptor, an inverse agonist decrease the constitutive activity by 
stabilizing the inactive conformation of the receptor.  Moreover, ligands can bind to a 
GPCR at the same site as the native ligand or to other sites, being called as 
Figure 1: Structural characteristics of GPCRs. GPCRs have common structural characteristics, being composed 
by an N-terminus, followed by seven α-helices (TM helices 1-7), interconnected by loops of different lengths at both 
extracellular (ECL 1-3) and intracellular (ICL 1-3) sides, and a C-terminus. Most of the differences observed between 




orthosteric ligands or allosteric ligands/modulators, respectively. Allosteric ligands 
can alter several aspects of the dynamics, structure and function of a GPCR, such 
as: increase or decrease the affinity or influence the efficacy of orthosteric ligands; 
induce the activation of the receptor, even when there is not a orthosteric ligand 
(Fig.2B). When different receptors present identical orthosteric sites allosteric 
modulators may achieve selectivity between receptor subtypes. The GPCR’s activity 













GPRCs transmit signals into cells via activation of the G-proteins. These 
proteins activate effector proteins, initiating a cascade of events and culminating with 
an activation or inhibition of certain proteins, such as enzymes, proteins associated 
with vesicular transport and ion channels. The messenger molecule, the associated 
G-protein, and the GPCR type influence the activated pathway. Indeed, the activation 
of a receptor by an agonist induces the modulation of the activity of a large number of 
enzymes and ion channels  such  as  potassium channels, calcium channels, 
phospholipases, adenylyl cyclase, Ser/Thr protein kinases, and G  protein-coupled  
receptor  kinases  (GRKs)  to  activate  further  downstream  signalling cascades. 
This event can also cause  various  intracellular  alterations  in  the  levels  of second  
messenger  molecules  such  as  cAMP,  intracellular  Ca2+, inositol  triphosphate  
(IP3),  cAMP  response  element  binding  protein (CREB) and diacylglycerol  (DAG) 
(1,2).  
G-proteins are composed by three subunits, α,   and   and Gαs can be 
classified into distinct families: Gαs activates adenylyl cyclase, inducing the cAMP - 
protein kinase A (PKA) signaling cascade and can be over-activated by the cholera 
Figure 2: The type of ligands influences the response of the GPCR. (A) Dose-response curve of a cellular 
response according to the type of ligand. (B) Orthosteric and Allosteric ligands. (Adapted from: Saengsawang & 






















toxin; Gαi/o inhibits adenylyl cyclase (AC), activates c-Src tyrosine kinases and can 
be inactivated by the pertussis toxin; Gαq/11 that activates phosphoinositide 
phospholipase C  (PLC ), inducing the IP3 – protein kinase C (PKC) signaling 
cascade, Gα12/13  allows Rho (a family of small signalling G proteins) activation, and 
Gαtransducin  which activates cyclic guanosine monophosphate (cGMP) 
phosphodiesterase in the retina (Tab. 1) (2). 
Table 1: Signalling pathways activated according to the Gα Family 
Gα Family Signaling Pathway Activated 
Gαs Activation of adenylyl cyclase  Induction of cAMP-PKA signaling cascade 
Gαi/o Inhibition of adenylyl cyclase  Activation of c-Src tyrosine kinases 
Gαq/11 Activation of PLC   Induction of IP3-PKC signaling cascade 
Gα12/13 Rho activation 
Gαtransducin Activation of cGMP phosphodiesterase in the retina 
 
When in a resting state, the G-protein can bind to an active or inactive GPCR 
or drift in the membrane. The three subunits of G-proteins are bound tightly to each 
other and to the membrane. Gα is bound to the guanosine diphosphate (GDP) 
nucleotide and Gβ is tightly bound to Gγ via nonpolar interactions. The Gα and the 
Gγ subunits are covalently attached to the membrane (2). 
When a GPCR is activated, the G-protein switches to an active state, 
emerging a conformational change in the Gα, leading to: 1) the conversion of GDP 
into guanosine-5'-triphosphate (GTP) by Gα (this subunit has GTPase activity); 2) the 
departure of Gβγ complex, which, in its turn, can bind to effectors equivalent or 
different from those of Gα; 3) the binding of Gα to an effector protein; 4) and 
activation of the effector protein (Fig. 3 – 1,2,3) (2).  
After a short time, Gα suffers a conformational change, caused by the 
hydrolysis of GTP to GDP. Since the GTPase activity of Gα it is not too fast enough 
for the cellular response requirements, in order to accelerate this process, G-proteins 
interact with proteins called ‘regulators of G protein signalling’ (RGSs).  This allows 
the reattachment of Gα with Gβγ complex, restoring the resting state and preparing 




Figure 3: GPCR signaling cycle. (1) When an agonist binds to extracellular domain of the inactive GPCR, the G-
protein binds to the intracellular domain of the receptor. (2) Conversion of GDP into GTP in Gα’s nucleotide 
binding, site, (3) leading to the separation of Gα from Gβ  and, successively,  to the binding of the Gα subunit to 
an effector protein, initiating the signalling cascade.(4) After a short time, the bound between GTP and Gα is 
hydrolysed and this subunit separates from its effector protein, re-binding to Gβ  complex. This last step restores 
the resting state and the system is prepared for another cycle (Adapted from: Saengsawang & Rasenick 2015). 
The formation of heterodimers (dimers or oligomers) is also possible. This 
suggests that intracellular signalling can change under different conditions and it may 
have an important role in GPCR signalling transduction, crosstalk between signalling 
pathways and regulation of GPCR activity (2,4). 
In order to avoid the over-stimulation, after activation of the downstream 
signalling pathway, the receptor is desensitized by two distinct processes: 
homologous desensitization or heterologous downregulation. Homologous 
desensitization is mediated by the phosphorylation of the C-terminal of the receptor, 
which allows the interaction between the GPCR and arrestin proteins, ending the 
signalling, by preventing the interaction of the receptor with its related G-protein, and 
inducing the internalization by clathrin-coated vesicles, that can by either recycled to 
the cell membrane or lead to the degradation of the receptor. Heterologous 
downregulation acts on other membrane receptors (and not on the active GPCR) and 
its mediated by second messenger-activated kinases, like PKA or PKC. When the 
receptors stimulation is prolonged, the downregulation mechanisms are more 










1.1. GPCRs as therapeutic targets 
These receptors have a large membrane distribution and can be involved in 
numerous physiologic and pathophysiologic processes, the GPCRs are targets of 
about 60% of the clinically prescribed drugs (2,6). 
Table 2: Examples of GPCR-targeting drugs (Adapted from: Saengsawang & Rasenick 2015) 

















Asma or Chronic Obstructive 



























The drugs can bind directly to the GPCR or can change the GPRC’s activity by 
affecting other proteins, being called directly or indirectly acting drugs, respectively. 
Directly- acting drugs, in its turn, can be classified into orthosteric drugs, when the 
molecule binds to the orthosteric site of the receptor, acting as agonist, antagonist or 
inverse agonist, or into allosteric drugs, binding to the allosteric site and modulating 
the activity of GPRC or changing its affinity for the natural ligand (2). 
The interest of the pharmaceutical industry in the development of allosteric 
drugs is enormous. This type of drugs allows more precise control of the activity of 
the GPCR and, since the allosteric sites are less conserved than orthosteric sites, 
allosteric drugs tend to be more subtype selective. However, the design of these 
drugs is complex since it necessitates the knowledge of active and inactive 
conformations, requiring the crystallization of the receptor with several ligands. 
Cinacalcet, for the treatment of hyperparathyroidism, and Maraviroc, for the 
prevention of cellular entry of Human Immunodeficiency Virus 1 (HIV-1), are 
examples of a positive allosteric modulator of the CaSR and of a negative allosteric 
modulator of the chemokine receptor C-C chemokine receptor type 5 (CCR5), 
respectively (2,8).  
GPCR drug discovery is moving towards finding more effective, selective 
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molecules that minimize adverse effects. Thus, in order to achieve these goals, the 
focus is to design biased-ligands – that activate a specific signalling pathway, 
increasing the specificity and decreasing side effects -, dual acting  drugs – bind to 
different receptors or other proteins producing a combined effect, potentializing him-, 
monoclonal antibodies (mAbs) – bind to the desired GPCR and modulate their 
activity -, and drugs that affect the trafficking or desensitization of the receptor (2).  
By the end of the year 2017, were identified 475 approved drugs that act at 
108 different GPCRs, accounting for approximately 34% of all Food and Drug 
Administration (FDA) approved drugs. 321 molecules (68% of the total number of 
approved drugs) were in clinical trials, of which about 20% targeted 66 potentially 
novel GPCR targets without an approved drug. Between 2013 and 2017, 69 new 
GPCR-targeting drugs were approved by FDA (8).  
Table 3: Examples of new molecules acting via GPCR approved by the FDA between 2014 and 2017 
(Adapted from: Hauser et al. 2017) 































Orphan GPCRs serve as possibly novel targets for several pathologies and 
may provide more selective therapeutic targets, resulting in the potential reduction 
inside effects. The study of currently unknown signalling transduction pathways may 
allow the development of new drug design strategies. Examples of orphan receptor 
that are promising therapeutic targets include G-protein coupled receptor 55 
(GPR55) as antispasmodic target, G-protein coupled receptor 35 (GPR35) as a 
target in allergic inflammatory condition or G-protein coupled receptor 84 (GPR84) in 
ulcerative colitis. The number of orphan GPCR-target drugs entering into clinical 
trials is increasing (3,8).  
The therapeutic indication of GPCR-targeting drugs covers several and 
diverse diseases. The number of indications seems to be increasing, expanding from 
areas such as hypertension, depression, analgesics and schizophrenia, to new areas 
such as diabetes, obesity and several central nervous system (CNS) disorders (8).  
More than 50% of non-olfactory GPCRs are expressed in the cerebral cortex 
and disfunctions in the neurotransmission mediated by these receptors can lead to 
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Figure 4: Number of agents approved versus number of drugs in clinical trial according to the 
pathology. Allergy and hypertension are the pathologies with more drugs approved, while diabetes and 
cancer are the diseases with more agents in clinical trials (Adapted from: Hauser et al. 2017).  
several disorders. GPCRs can be a target for diseases like Alzheimer’s Disease 
(AD), Multiple Sclerosis (MS), Huntington’s Disease (HD), and others. Therapies for 
CNS diseases account with approximately 124 (26%) of all FDA approved GPCR-








For instance, fingolimod, a sphingosine 1-phosphate receptor 1 (S1P1) 
modulator, is a therapeutic approach in MS, reducing relapse and slowing down the 
progression, and it is a GPCR-targeting drug (8). In AD, Serotonin (5-HT) receptor 
modulators raise huge interest for scientists, comprising serotonin receptor 6 (5HT6) 
receptor antagonists. These last molecules increase the release of acetylcholine, 
improving the disease symptoms (8).  
Diabetes is another pathology whose therapies include a high percentage of 
GPCR-targeted agents: 9% of the total number of drugs in clinical trials in 2017 
belongs to GPCR-targeting drugs for diabetes and obesity. The glucagon-like peptide 
1 (GLP1) receptor agonist exenatide was the first GPCR-targeted agent approved for 
type II diabetes (T2D), followed by liraglutide, dulaglutide, albiglutide and lixisenatide. 
In recent years, several other receptors are being studied as GPCRs targets for 
diabetes, such as G-protein coupled receptor 119 (GPR119) and free fatty acid 
receptor 1 (FFAR1) (8,9).  
Opportunitie for GPCR-targeted agents for cancer’s therapy are also 
emerging, playing an important role in cancer initiation, progression and 
metastasization. Degarelix, a gonadotrophin realising hormone (GnRH) receptor 
antagonist used for advanced prostate cancer, sonidegib and vismodegib, both a 
smoothened (SMO) receptor inhibitors and approved for basal cell carcinoma, are 




2. Cannabinoid receptors 
The endocannabinoid system (ECS) has an important role in several 
physiological and pathological processes, as pain modulation, fertility, 
neuroprotection, immune function, cancer, cardiovascular diseases and appetite. It is 
composed by the endocannabinoids, the cannabinoids GPCRs and by the enzymes 
responsible for its biosynthesis and degradation (11).    
Endocannabinoids are endogenous lipid-signalling molecules that act like 
agonists of cannabinoid receptors. In 1992 the first endocannabinoid were identified, 
the N-arachidonyl ethanolamine (anadamide or AEA), followed by the identification of 
2-arachidonyl glycerol (2-AG) in 1995(11). Also in the early 1990s, two cannabinoid 
receptors were identified, by molecular cloning, that can bind with high-affinity to 
anandamide and 2-AG: cannabinoid receptor type 1 and type 2 (CB1 and CB2, 
respectively)(11). These cannabinoid receptors belong to class A of GPCR 
subfamily. Later on, three orphan GPCRs, G-protein coupled receptor 18 (GPR18), 
GPR55 and GPR119, have been linked to the ECS, since they exhibit homology with 
the established CB1 and CB2 (11,12).  
 
 
3. Cannabinoids compounds and endocannabinoids 
In 1965, Raphael Mechoulam identified the Δ9-tetrahydrocannabinol (Δ9-THC), 
a lipophilic phytocannabinoid extracted from cannabis plant. This compound and 
other lipids also derived from cannabis plant showed the capacity of activate GPCRs, 
which generated the hypothesis that an endogenous ligand, most probably a lipid, 
must be produced (13).  
Mechoulam’s group identified, in 1992, an endogenous analogue of Δ9-THC 
from porcine brain, the AEA. This endocannabinoid has a molecular structure similar 
to endogenous N-acyl amide signalling molecules, a family of novel endogenous 
signalling molecules with a wide-range of cellular signalling potential. Both Δ9-THC 
and AEA showed ability to activate the CB1 and induce physiological responses as 
hypothermia, analgesia, hypoactivity and catalepsy. AEA also binds to the CB2 and 
activates the transient receptor potential vanilloid type-1 channel (TRPV1)(13). 2-AG 
was the second endogenous cannabinoid lipid identified, in rat brain and canine gut. 
It also binds to both CB1 and CB2(13). The identification of both AEA and 2-AG 
opened a path to the identification of other agonists, which are primarily N-acyl 
amides in structure (13).  
Five structurally distinct classes of cannabinoid compounds have been 
identified: classical cannabinoids, like Δ9-THC, Δ8-THCdimethylheptyl (HU210); 
bicyclic cannabinoids, as CP55.940; indole-derived cannabinoids, as WIN 55,212; 
eicosanoids, including the endogenous ligands AEA and 2-AG;  and 









4. CB1 and CB2: two cannabinoid receptors 
CB1 and CB2 are two cannabinoid receptors that were identified about 20 
years ago. They belong to the GPCR family class A and are coupled to Gi/o 
heteromeric G protein. CB1 receptor could also couple to Gs protein (12,15,16). 
These receptors mediate the effects of Δ9-THC and of the endocannabinoids 
AEA and 2-AG, however, they also have differences in their pharmacology (14).  
The human CB1 receptor gene (CNR1) is located on human chromosome 
6q14-15, while the human CB2 receptor gene (CNR2) is located at chromosome 
1p36. Several polymorphisms and alternative splice variants for both receptors have 
been identified, and these variations have been associated with the development of 
some diseases or to different pharmacologic responses. For example, several 
studies linked have polymorphisms of the human CB2 gene to osteoporosis (14). 
Interestingly, the CB1 receptors are highly conserved among vertebrate 
species and have also been found in some invertebrates. For instance, the human 
CB1 receptor presents an homology of 93% at the nucleic acid level and 97% at the 
amino acid level to the rat receptor (14). The CB2 receptor, initially isolated from a 
type of human leukaemia cell line called HL60 cells, shows a homology of 44% at the 
amino acid level with the CB1 receptor, representing a receptor subtype, with similar 
binding profile. Nevertheless, this receptor is less conserved between species than 
CB1 (14).  
The CB1 receptors are highly expressed in the central nervous system, being 
one of the most abundant GPCRs in the brain. They mediate most of the 
psychoactive effects and play a role in the control of motor function, cognition, 
memory and analgesia, what can be correlated with their distribution: they are 
primarily localized in the terminals of central and peripheral neurons, where they 
mediate inhibition of neurotransmitter release (12,14,15). 
CB1 is expressed in lower levels in several peripheral tissues, as the heart, 
lung, liver, bone marrow, thymus, adrenal gland, prostate, uterus, ovary, testis, vas 
deferens and tonsils. It was detected in many circulating immune cells, being that the 
expression of CB1 receptors appears to increase or decrease during immune cell 
activation (12,14,15).  
CB2 receptors are abundantly expressed in peripheral organs with immune 
function, like spleen, thymus, tonsils, macrophages, leukocytes, lung and testes, 
mediating immunosuppressive effects. In situations of inflammation and immune cell 
activation, CB2 receptors are upregulated. Besides the fact that these receptors are 
expressed in lower levels than CB1, they also play a clear role in CNS activity and in 
immune responses (12,14,15,17).  
 
4.1. Ligands and therapeutic applications 
 When a compound can target CB1 or CB2 receptor, it is classified as a 
cannabinoid. According to their functionality, they can be divided as agonist (after 
binding to the receptor, is verified an increase in the basal level of signalling), inverse 
agonists (downregulate the signalling when binding to the receptor) or antagonists 
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(act on the agonist or inverse agonist activity, by decreasing their effect). According 
to their origin, they can be classified as plant derived or phytocannabinoids, 
endogenous or endocannabinoids, and chemically synthesized or synthetic 
cannabinoids. Chemical structures of some cannabinoids are shown in Figure 5  
(4,8).  
Endogenous ligands of CB1 and CB2 receptors, such as AEA, 2-AG and 
noladin ether, are produced in several peripheral tissues, including liver, bone, 
gastrointestinal tract, skin, reproductive and immune system (18). 
Several CB2 ligands are only relatively selective, because most of the 
commonly CB2 ligands have evolved from molecules that have appreciable affinity 
for CB1 receptors. For instance, both receptors can be activated by (–) 11-hydroxy-
Δ8-THC-dimethylheptyl (HU-210), CP55.940, and R-(+)-WIN55212 (11). The majority 
of the agonists show little selectivity between the CB1 and CB2 receptors, while 
highly selective antagonists have been found, allowing the discrimination of CB1 and 






























Δ9-THC structure was the starting point for synthesizing and studying chemical 
analogues. After the discovery of Δ9-THC and anandamide, in 1994, the first CB1 
receptor selective antagonist, the SR141716A (Rimonabant), with a 1000-fold higher 
affinity for CB1 than for CB2 was reported. In 1997, SR144528 was discovered as a 
Figure 5: Chemical structures of some cannabinoids. (A) Examples of Phytocannabinoids; (B) Examples of 
Synthetic Cannabinoids; (C) Examples of Endocannabinoids. (Adapted from: González-Hernández et al. 2019) 
(A) Phytocannabinoids 




Figure 6: Chemical Structures of SR141716A. (Adapted from: Han et al. 2014) 
antagonist/inverse agonist for the CB2 receptor, sharing the pyrazole core structure 













CB1-selective antagonists include AM251 and AM281, while agonists are, for 
example, R-(+)-methanandamide, arachidonyl-2′-chloroethylamide, arachidonyl-
cyclopropylamide and O-1812. Nevertheless, CB1 ligands have a limited use since 
they can provoke serious psychotropic side effects. For example, since CB1 receptor 
has an important role in the control of food intake and energy balance, several 
antagonist and inverse agonists were developed in order to treat obesity and 
diabetes, which was the case of Rimonabant. This compound was used as an anti-
obesity drug, although the profile between benefit and risk was not favourable, due to 
psychiatric side effects, and Rimonabant was withdrawn  from the market  in 2008 
(5,13,19). 
In contrast, activation of CB2 receptors does not appear to produce these 
psychotropic effects, so selective modulation of CB2 receptor has being considered 
an interesting therapeutic approach, being devoid of central side effects (13,19). 
Selective agonists of CB2 have been considered a promising therapeutic for 
the treatment or management of a range of painful conditions, for treat 
neuroinflammatory or neurodegenerative diseases, such as Parkinson´s Disease 
(PD), AD, MS, amyotrophic lateral sclerosis (ALS), HD and stroke, for peripheral 
disorders that involve inflammation, including atherosclerosis, inflammatory bowel 
diseases, ischemia/reperfusion injury, renal fibrosis and liver cirrhosis. CB2 agonists 
have shown efficacy in preclinical cancer models and there are epidemiologic and 
preclinical data that suggest that these compounds show a protective role in 
osteoporosis and arthritis (13,19). 
There are many identified CB2 receptor agonists, including classic 
cannabinoids (Δ9-THC, L759633, L759656, JWH133, KM233), nonclassic 
cannabinoids (CP55940, HU308), aminoalkylindoles (WIN55212-2, AM1241, 
STS135, JWH015, GW405833, UR144, MAM2201, AM2232, AM2233, AM1248), 
thiazoles (A836339), thiazoles (A836339), tricyclic pyrazole (GP1a), cannabilactone 
(AM1710), carboxamides (SER601, 4Q3C), pyrimidine analog (GW833972A), 
eicosanoids (2AG, methanandamide), plant products (4-Methylhonokiol, (E)b-
caryophyllene (BCP)). The CB2 receptor antagonists include AM630, JTE907, 
SR144528. The CB2-selective agonists are JWH133, HU308 and AM1241 and 
selective antagonists are SR144528 and AM630 (5,15). 
24 
 
Figure 7: Chemical Structures of the CB2 receptor selective agonists S-777469 (left) and GW842166X (right) 
(Adapted from: Han et al. 2014) 
In 2007, the GlaxoSmithKline (GSK) research group reported a selective 
agonist for the CB2 receptor, the compound GW842166X. The phase II studies of 
this compound have been completed for evaluating its analgesic efficacy for dental 
surgery and for the treatment of osteoarthritis pain of the knee, according to the 
United States National Institutes of Health (NIH)(15). The CB2 receptor selective 
agonist S-777469 and inverse agonist JTE-907 were found to be effective in 
suppressing spontaneous itch-associated responses in the mice model of atopic 
dermatitis, respectively. Recently, S-777469 has also been reported on completing 











Despite of all the studies and developments, CB2 agonists still have a limited 
success in clinical trials, due to diverse factors including the immune system side 





5. GPR55 and GPR18: two distinct orphan receptors 
Despite the fact that GPR55 and GPR18 directly or indirectly interact with 
cannabinoids, the Subcommittee on Cannabinoid Receptors of the International 
Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature 
and Drug Classification (NC IUPHAR) decided that GPR55 and GPR18 do not meet 
all the requirements to be consider as novel cannabinoid receptors. Thus, they have 





The orphan GPR55 was identified in 1999 by Sawzdargo et al., that isolated 
and cloned the human GPR55 (hGPR55). This receptor belongs to the rhodopsin-like 
(Class A) family of GPCRs. It is composed by a 319 a.a. sequence, encoded by the 
GPR55 gene was mapped to human chromosome 2q37. Has been reported that 
GPR55 couples to Gα12/13 or Gαq proteins (1,11,13,14,17).  
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Figure 8: Chemical structures of the GPR55 ligands LPI (left) and 2-AGPI (right). (Adapted from: Reggio & 
Shore 2015) 
GPR55 exhibit some similarity in terms of the amino acid sequence with 
GPR35 (27%), lysophosphatidic acid receptor 6 (P2Y5) purinergic receptor (29%), G-
protein coupled receptor 23 (GPR23) (30%), and C-X-C chemokine receptor type 4 
(CXCR4) (26%). Nevertheless, although it shares many cannabinoid ligands with 
CB1 and CB2, GPR55 has low a.a. identity with these two cannabinoid receptors, 
having a similarity of 13.5% with CB1 and 14.4% with CB2 (13,14). 
hGPR55 is highly expressed in the CNS, and is also expressed in peripheral 
tissues such as endothelial cells, adrenal glands, kidney, bladder, gastrointestinal 
tract, liver, lung, uterus, bone and other tissues/organ systems. More recently, high 
levels of GPR55 were also found on lymphocytes and spleen, as well as on many 
cancer cells, in which the expression levels correlate with the rate of cancer cell 




L-α-lysophosphatidylinositol (LPI) was the first endogenous ligand identified for 
this receptor, by Oka et al. in 2007. LPI is produced from membrane 
phosphatidylinositol through the catalytic activity of Ca2+-dependent phospholipase 
A1 (PLA1) or Ca2+-independent phospholipase A2 (PLA2). In 2009, the same authors 
demonstrated that the addition of an arachidonic fatty acid chain (2-arachidonoyl-sn-
glycero-3-phosphoinositol; 2-AGPI) to LPI produced the most biologically active LPI 
species. Interestingly, the structurally related endogenous lipid, the lysophosphatidic 
acid (LPA), does not activate GPR55. Even though LPI and 2-AGPI are ligands for 
GPR55, they do not activate CB1 or CB2 receptors, being non-cannabinoid ligands 
(5,11,13,22). 
Actually, GPR55 binds to several cannabinoid compounds, so after being 
initially deorphanized as a cannabinoid receptor, it still is presented as the main 
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Figure 9: Chemical structures of O-1602 (left) and AM251 (right). (Adapted from: Reggio & Shore 2015) 
GPR55 signaling is modulated by the endocannabinoids 2-AG, virodhamine, 
noladin-ether, oleoylethanolamida (OEA) and palmitoylethanilamida (PEA) and by 
the atypical cannabinoids cannabidiol (CBD) and abnormal-cannabidinol (abn-CBD; 
4-[(1R,6R)-3-methyl-6-prop-1-en-2-yl-1-cyclohex-2-enyl]-5-pentylbenzene-1,3-diol) 
(3,20). 
Several studies described HU210 (a synthetic analogue of Δ9-THC), JWHO15 
(a CB2 receptor agonist), AEA (in a much higher concentration than the one required 
to CB1 activation) and R-methanandamide, CBD and its synthetic analogue O-1602 
(5-methyl-4-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]benzene-1,3-diol) 
as GPR55 agonists. Although, other studies indicated that CBD may act as a GPR55 
antagonist (3,20). 
Other cannabinoid ligand, the CB1 antagonist AM251 also showed high affinity 













Rimonabant is another CB1 antagonist that demonstrated agonist activity on 
GPR55. However, similarly to what was described for CBD, there are studies that 
report a blockage of GPR55 signaling responses to agonist compounds, like AEA or 
JWH015, by Rimonabant. CP55940, a cannabinoid agonist, showed partial 
agonist/antagonist activity in GPR55 (3,20). 
GPR55 shows affinity and responds to non-cannabinoid ligands. For example, 
GSK494581A (1-{2-fluoro-4-[1-(methyloxy)ethyl]phenyl}-4{4-fluoro-4-(methylsulfonyl)-
2-biphenylyl]carbonyl} piperazine) activates selectively the GPR55, at low nanomolar 
potency. Compounds such as ML191 (CID23612552), ML192 (CID1434953) and 
ML193 (CID1261822) act as non-cannabinoid GPR55 antagonists.  CID16020046 is 
another non-cannabinoid GPR55 antagonist, although this compound inhibit 
selectively this GPRC, not having shown any activity on CB1 or CB2 (3,20). 
 
 
5.1.2. Therapeutic applications 
LPI had been associated to essential biological processes such as induction of 
insulin release, mediation of hepatic vitamin D3-modulating Ca2+ metabolism and 
mitogenic modulation in neuronal and endothelial cells. Conjugating LPI and the 
processes mentioned above, with GPR55 expression and distribution, one can 
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envision that GPR55 can be a therapeutic target in the several diseases such as 
obesity and diabetes, osteoporosis, in cancer therapy and others (3,20). 
The expression of GPR55 in β-cells of the islets of Langerhans indicates that 
these receptors play an important role in glucose homeostasis by the regulating 
insulin secretion. Therefore, using GPR55 agonists might be a therapeutic approach 
in T2D, increasing insulin secretion and sensitivity. In agreement, some studies 
showed that abn-CBD has glucose-lowering and insulinotropic potential (20,23). 
This receptor can also be a potential therapeutic target in PD due to a possible 
alteration on its expression in the basal nuclei, where it is related to procedural 
memories. Pharmacological studies showed that CBD might prevent the pro-
inflammatory glial cell activation induced by the beta-amyloid administration and 
might attenuate the induced dopaminergic system impairment in rats. However, 
clinical trials with CBD showed lack of pro- or anti-parkinsonian effects.  Furthermore, 
it is possible that some antiepileptic actions observed with phytocannabinoids involve 
the blocking of GPR55 (5,23). 
Recent studies revealed that LPI and GPR55 are important factors in cell 
proliferation and migration, and a correlation between GPR55 expression and/or LPI 
levels and cancer progression/aggressiveness has already been detected. For 
example, LPI can be considered a marker of poor prognosis for patients with ovarian 
cancer. There are also evidences of GPR55 overexpression in several tumour cells, 
including breast cancer, melanoma, ovarian cancer, glioblastoma, and others Several 
studies described that the β2-adrenergic agonist AMF ((R,R´)-40-methoxy-1-
naphthylfenoterol), a GPR55 inhibitor, blocked the GPR55 agonist effect of O-1602 
and AM251 in cancer cell lines, reducing chemoresistance of cancer cells (20,22). 
 GPR55 is expressed in osteoblast and osteoclasts, and LPI has been shown 
to stimulates bone reabsorption. Therefore, inhibiting GPR55 signaling might be 





GPR18 belongs to the class A or rhodopsine like GPCRs. It consists in a 
sequence of 331 amino acids, encoded by the GPR18 gene which is localized in the 
chromosomal region 13q32.3. This receptor was described for the first time in 1997 
and interacts with Gαi/o, Gαq/11, and Gα12/13, but it has been suggested that 
GPR18 modulate the transduction pathways of these G proteins in a ligand 
dependent way (11,12,13,19,21).  
The expression of hGPR18 varies according to the tissue or organ: GPR18 
mRNA has moderate to high expression in testes, thyroid, peripheral blood 
leukocytes, lungs and specific brain regions, such as hypothalamus, cerebellum, 
brain stem and striatum; while in the spleen, thymus, ovaries, uterus, stomach and 
intestines it shows a low to moderate expression. Finally, low or undetectable 
hGPR18 mRNA levels were detected in the heart, lungs, liver, kidney, pancreas, 
colon, skeletal muscle, skin, placenta, prostate, adrenal medulla, adrenal cortex and 
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Figure 10:Chemical Structure of N-arachidonoylglycine (NAGly) (Adapted from: Schoeder et al. 2018) 
in some brain areas like amygdala, frontal cortex, hippocampus, cerebellum, 
thalamus and brain stem (5,11,12,21) 
Based upon the expression pattern of this receptor, it is suggested that 
GPR18 has a potential role in the control of immune system activity, such as 




Kohno and collaborabors identified the acylamino acid N-arachidonoylglycine 
(NAGly) as an endogenous agonist for GPR18, by screening a bioactive lipid library 












NAGly is a metabolite of the endocannabinoid anandamide and is a member 
of a subfamily of lipoamino acids. It can be detected in high levels in mammalian 
nervous tissues, especially in spinal cord and brain. Some studies showed that cells 
are able to convert anandamide to NAGly. The chemical similarity between NAGLy 
and anandamide created the hypothesis that GPR18 could be the third cannabinoid 
receptor. Besides that, GPR18-mediated cellular signalling, in response to NAGly 
and anandamide, was describe through an inhibition of cAMP, phosphorylation of 
extracellular-signal-regulated kinase (ERK), and other effects such as regulation of 
cellular migration and proliferation/apoptosis. The characterization of GPR18 as a 
cannabinoid receptor is also supported by studies that found that the 
phytocannabinoid Δ9-THC and the synthetic cannabinoids abn-CBD and O-1602 act 
like GPR18 agonists (5,11,12,15,17,19,21).  
One of the most significant data impeding the deorphanisation of GPR18, is 
the non-totally overload distribution of GPR18 by the different tissues and NAGly: the 
highest levels of NAGly, in rat, were found in the spinal cord, small intestine, kidneys 
and skin, while lowest levels were found in testes and spleen (organs that present a 
moderate expression of GPR18). Nevertheless, it can be hypothesized that NAGly is 
synthesised when a system actively induces its synthesis, as it happens with AEA 
and 2-arachidonyl glycerol (18). 
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Figure 11: Chemical Structure of Resolvin D2 (RvD2) (Adapted from: Schoeder et al. 2018) 
Figure 12:Chemical Structure of Amauromine (Adapted from: Schoeder et al. 2018) 
The activation of GPR18 by NAGly leads to apoptosis of inflammatory 
leukocytes, which in turn reduces local inflammation. This is an example of a finding 
that suggests a physiological function of NAGly via GPR18 in an inflammatory 
process. Nevertheless, the responsivity of GRP18 to activation by NAGly has been 
brought into question Several reports described GPR18 to be completely 
unresponsive towards NAGly and other studies suggest that signaling properties of 
GPR18 may be cell type specific (5,12,15,19,21). 
Despite the similarity among NAGly and anandamide, NAGly did not showed 
affinity for either CB1 and CB2, what can be explained by the structural modification 
in NAGly (oxidation state of the beta carbon to the amide nitrogen). NAGly is not a 
specific agonist for GPR18, it can also activate other receptors, such as G-protein 
coupled receptor 92 (GPR92). GPR18 is also activated by the endocannabinoid AEA 
and THC, demonstrating to be full agonists at GPR18. While CBD and AM251 act as 
weak partial agonists, a number of other agonists of CB1 and CB2 cannabinoid 
receptors were inactive (WIN55212-2, CP55940, JWH015, and JWH133) 
(5,11,15,19,21). 
 In recent studies, resolvin D2 (RvD2) was proposed as an endogenous 
agonist of GPR18. RvD2 is a natural lipid that showed capacity to activate 
recombinant human GPR18 receptors in a receptor- and ligand-dependent manner 
and it was found that this compound exhibit ant-inflammatory effects on 











The only GPR18 receptor antagonist described until the date is amauromine, a 












Repel and coworkers and Schoeder and collaborators developed several 
synthetic GPR18 antagonists.  The first potent GPR18 antagonist developed by this 
group was the (Z)-2-(3-(4-chlorobenzyloxy)benzylidene)-6,7-dihydro-2H-imidazo[2,1-
b][1,3]thiazin-3(5H)-one (PSB-CB-5). PSB-CB-5 behaved as a partial antagonist, and 
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Figure 13: Chemical Structure of PSB-CB-5 (Adapted from: Schoeder et al. 2018) 
it showed a certain degree of selectivity. After the developedment of the PSB-CB-5, 
several analogs were synthesized through modifications of the heterocyclic core and 
variations of substituents at the benzylidene in order to design a molecule more 
potent and selective. These analogs include PBS-CB-27, the compound with good 
















5.2.2. Therapeutic applications 
Although potential therapeutic approaches targeting GPR18 need further 
investigation, the distribution and expression of GPR18 suggests that this receptor is 
implicated in the pathophysiology of several disorders and its regulation plays an 
important role in these ones. 
GRP18 expression was found significantly increased in proinflammatory M1 
mouse peritoneal macrophages and its activation also regulates leukocyte trafficking 
during acute inflammation. NAGly was also found to reduced cell viability of the same 
type of cells, not having any effect on M2 anti-inflammatory macrophages. These 
studies indicate that GPR18 is involved in the attenuation of the proinflammatory M1 
stage of macrophages and that NAGly is a potential anti-inflammatory factor. So, 
GPR18 is important in the regulation of cell death and in the immunological function 
and it might be a relevant therapeutic target for several inflammatory diseases 
(5,13,25). 
In the case of osteoarthritis, GPR18 is expressed in the degenerated 
chondrocytes within the deep zone of cartilage, suggesting that this receptor might 
be a target for the treatment of this pathology (5).  
The role of this receptor in pain has also been a research focus. Some reports 
showed that a nerve injury enhances GPR18 mRNA expression in the spinal cord, 
mediating a few analgesic effects and modulating neuropathic pain. NAGly 
upregulated GPR18 mRNA in spinal cord after sciatic nerve injury as well (1,5,16). 
 Other disorders where GPR18 might be used as a target are obesity and 
diabetes. Obesity is considered a chronic inflammation and, endogenous GPR18 
ligands, have been shown to be modulated by dietary factors. GPR18 ligands are 
also linked to insulin resistance: for example, studies performed in rat models 
showed that NAGly increases insulin secretion. Recently, it was additionally 
31 
 
emphasized that GPR18 activation in diabetes reverse myocardial oxidative stress 
and dysfunction, protecting the cardiovascular system (25). 
Supporting the theory that GPR18 mediates cell proliferation and antiapoptotic 
signalling, a group of scientists described the increase of apoptosis rate of melanoma 
cells when treated with short interference RNAs (siRNAs) against GPR18 mRNA. 
This finding supports the hypothesis of targeting GPR18 for the treatment of several 
type of cancers (25).     
More therapeutic approaches are being studied and the hypothesis are being 
explored, however the need of understanding the complex GPR18 signaling 





























Materials and Methods 
1. Cell Culture 
 The experiments were performed using Chinese Hamster Ovary (CHO) cells 
stably expressing the receptors of interest. 
In order to ensure cell viability, the cells were maintained in T75 culture flasks 
at 37ºC under a 5% CO2 atmosphere, and sub-cultured at different densities, 
depending on the experimental goal, when the degree of confluence reached 80-
95%. 
The growth mediums used varied according to the type of cells: for GPR18 
and GPR55 expressing cells the medium was F-12 supplemented with 10% of Fetal 
calf serum (FCS), 100 µg/mL or 100 U/mL of Penicillin/Streptomycin, 0.3 mg/mL of 
hygromycin and 0.8 mg/mL of Geneticin® (G418) Selective Antibiotic (Invitrogen™, 
Thermo Fisher); while for CB1 and CB2 expressing cells the medium was Dulbecco's 
Modified Eagle Medium: Nutrient Mixture F-12  (DMEM:F12) supplemented with 10% 
of FCS, 100 µg/mL or 100 U/mL of Penicillin/Streptomycin and 0.8 mg/mL of 
Geneticin® (G418). 
To split the cells, after the removal of the medium and after washing with 10 
mL of Phosphate Buffer Saline (PBS), 3 mL of a 0.05% trypsin solution was added to 
the cells. This solution is responsible for the enzymatic dissociation of cell-cell 
adhesion bonds and the disconnection of adherent cells from the growth surface. 
After confirming the cells detachment from the flask surface, 7 mL of new culture 
medium was added to the culture flask. The cell suspension was homogenized, to 
assure the complete dissociation of cells. The desired volume was taken to a new 
flask and were added 25 mL of medium. Cells were kept at 37ºC under a 5% CO2 
atmosphere. 
 
2. β-Arrestin Assay 
β-Arrestin PathHunter™ assay (DiscoveRx, Fremont, CA, USA) is a functional 
assay that uses PathHunter β-Arrestin cell lines (stable clonal cell lines), allowing the 
screening and the study of agonists and inhibitors of GPCRs. The fundament of this 
assay relies on the β-Arrestin recruitment to activated GPCRs.  
In order to study the effect of the compounds of interest in the GPCRs, 
measuring the activation status of the target receptor, an Enzyme Fragment 
Complementation (EFC) technology was used. This assay uses two fragments of β-
galactosidase (b-gal) enzyme, the Enzyme Donor (ED) and Enzyme Acceptor (EA). 
The target GPCR is tagged with a small fragment of b-gal called ProLink™, that 
works like the ED, while the β-Arrestin is tagged with the EA. Even though these two 
fragments separately have no enzymatic activity, when they are brought together, 
they form an active b-gal enzyme, which is capable of hydrolyze the substrate 
present in the PathHunter detection reagents, to generating light. 
To seed the cells, after the removal of the medium and washing with 10 mL of 
PBS, 10 mL of a dissociation buffer (2 mM EDTA-NaX2H2O, 10 mM glucose) were 
added to a 175cm2-flask of cells. After confirming the cells detachment from the flask 
surface, the cell suspension was homogenized, to assure the complete dissociation 
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of cells. The total volume was transferred to a 50mL tube and an aliquot of the cell 
suspension was used to count cell number using a Neubauer chamber. After a 5 
minutes centrifugation, the supernatant was discarded, and the pellet was 
resuspended in 10 mL of growth medium (F12 growth medium with 2% of FCS, 100 
µg/mL or 100 U/mL of Penicillin/Streptomycin, 0.3 mg/mL of hygromycin and 0.8 
mg/mL of G418).  
Cells were seeded into 96-well plates at a density of 40 000 cells/well for the 
cells expressing GPR18 and of 30 000 cells/well for the cells expressing GPR55, 24h 
before performing the assay, with 90 µL of growth medium (F12 growth medium with 
2% of FCS, 100 µg/mL or 100 U/mL of Penicillin/Streptomycin, 0.3 mg/mL of 
hygromycin and 0.8 mg/mL of G418). The cells were kept at 37ºC under a 5% CO2 
atmosphere. 
After 24 h, medium of GPR18 expressing cells were changed for 90 µL of the 
same medium without FCS, followed by an incubation of one hour to one hour and a 
half at 37ºC. For GPR55 expressing cells the assay was started immediately.  
For the preparation of the reagents, the compounds were firstly diluted in 
dimethyl sulfoxide (DMSO) at a concentration of 10 mM, and then diluted in PBS with 
10% of Bovine serum albumin (BSA), being the final DMSO concentration in the 
assay equal to 1%. 
For the agonist test, cells were incubated, for one hour and a half, with 10 µL 
of each compound. For the antagonist test, cells were incubated, for one hour, with 5 
µL of the compound of interest, followed by an one hour and a half incubation with 5 
µL of a known agonist of the receptor in study. 
After this period of time, 50 µL of detection buffer were added to each well and 
incubated for one hour. This buffer is composed by lysis buffer (for GPR18 cells: 
5mM K2HPO4, 5 mM KH2PO4, 150 mM NaCl, 10 mM MgAcetate, 2% CHAPS, pH 
7.5; for GPR55 cells: 10 mM Tris, 1 mM EDTA-Na x 2H2O, 100 mM NaCl, 5 mM 
MgCl, 1% Triton – X, pH 8), Emerald II ® (Invitrogen™, Thermo Fisher) and Galacton 
Star ® (Invitrogen™, Thermo Fisher). 
The luminescence was measured in a TopCount NXT (Packard, Perkin-
Elmer), for 1 second per well. 





3. Membrane Preparation 
This complex process allows the preparation of a membrane suspension, 
being that the membrane fraction contains the receptors of interest. 
One 175cm2-flask of cells was used to seed 20 dishes, and 1 mL of the cells of 
each 175cm2-flask was seeded in dishes with 20 mL of growth medium (DMEM-F12 
growth medium supplemented with 10% of FCS, 100 µg/mL of 
34 
 
Penicillin/Streptomycin and 0.8 mg/mL of G418). After the desired confluence has 
been reached, the medium was discarded, and the cells were washed with 5 mL of 
PBS. At this step, cells were frozen at -80ºC and the procedure was restarted the 
next day. To harvest the cells, 1.5 mL of scrapping buffer (2 mM Na2EDTA, 5 mM 
Tris) was added to each dish, and the resulting suspension was collected to a tube. 
Afterwards, the cells were homogenized using Ultra-Turrax® homogenizer 
(IKA Labortechnik). The homogenate was then centrifuged at high speed (50 000 g) 
for 5-10 minutes. The supernatant was discarded, the pellet was resuspended in the 
same buffer, and centrifuged again. After this last centrifugation, the supernatant was 
discarded, the pellet was resuspended in 50 mM Tris pH 7.4 and the membrane 
suspension was frozen at -80ºC.  
 
 
4. Lowry Method 
Lowry method is a colorimetric method used in the determination of the protein 
levels in several preparations. The first step consisted in the preparation of several 
solutions with crescent concentrations of BSA, in order to make a calibration curve. 
Then, the samples, in duplicate, were also diluted, in n Tris–HCl buffer, 50 mM, pH 
7.4  
Afterwards, 1000 µL of the reagent C (fifty parts of 2% Na2CO3 with 0.1 n 
NaOH, and one part of 0.5% Cu2SO4.5H2O with 1% Na-Tartrate in 50 mL of water) 
were added, followed by an incubation of 20 minutes. After this period, the reagent 
D/Folin & Ciocalteau’s Phenol Reagent Working Solution (18 mL of Folin – Reagent 
(F-9252) and 72 mL of H2O) were added and incubated by 30 minutes. Absorvances 
were measured in a spectrophotometer, at 500 nm (protein > 25 µg/mL) or at 750 nm 




5. Radioligand Binding Assay 
Radioligand (RL) binding assay is an assay that uses radioactively labeled 
drugs, being that these labelled molecules can bind to the receptor, transporter, 
enzyme or to the protein of interest. This assay allows the measuring of the rate and 
extension of binding, providing information about the number of binding sites, and 
their affinity and accessibility for various compounds.  
 [3H] CP55,940 was used as radioligand (final concentration 0.1 nM; specific 
activity = 141.2 Ci/mmol) and to calculate the volume of radioligand the following 
formula was used:  
    (μ ) =  
(           + 9) ∗                    
  
    
  ∗                               ℎ        (  ) ∗                    (  ) 





The final concentration of the protein for each well was 16 µg/well for CB2 
expressing cells, and 30 µg/well for CB1 expressing cells. To prepare the dilutions of 
the membrane preparation buffer (50 mM Tris, pH 7.4) was used. 
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All compounds were diluted in DMSO, and the final concentration of vehicle 
was 2.5%. 
The assay layout included 2 wells with 100% DMSO (representing the Total 
Binding of RL), 2 wells with 10 µM unlabelled CP 55.940 (final concentration; in 
DMSO; representing Non-Specific Binding of RL) and duplicates of the test 
substances in the established concentration. 465 µL of assay buffer (50 mM Tris, 3 
mM MgCl2, 0.1% BSA, pH 7.4) were pipetted into each well of a 96 well assay plate. 
Then, 15 µL of the test compounds, DMSO and unlabelled CP 55.940 were added at 
the corresponding wells, followed by the addition of 60 µL of RL. Finally, 60 µL of 
diluted membrane were added into each well to begin the reaction, following an 
incubation of 2 hours. About 30 minutes before harvest the RL-protein complex, the 
GF/C glass fiber filter was placed into 0.3% aq. polyethyleneimine solution, in order 
to reduce the binding of RL into the filter. 
A Brandel 96-channel cell harvester (Brandel, Gaithersburg, MD), was used to 
harvest the cells with cold (4ºC) washing buffer composed by 50 mM Tris, 0.1% BSA, 
pH 7.4. Each well was washed 3 times with 1 mL of cold washing buffer.The filter 
was dried at 50ºC for 1 hour. Afterwards, 50 µL of scintillation cocktail (Multiscint 25, 
PerkinElmer) were added to each well and the determination of the radioactivity 
bound to the receptor was performed in a liquid scintillation counter (Topcount NXT, 
Packard/Perkin-Elmer) using a 10 hours preincubation program.  




6. cAMP Accumulation Assay 
 Inhibition of adenylate cyclase activity was determined in CHO cells stably 
expressing the CB1 and CB2 receptor subtype, using a competition binding assay for 
cAMP, adapted from the procedure described by Nordstedt et al (26). 
Cells were seeded, according to the method described above, into a 24-well 
plate at a density of 200 000 cells/well 24 hours before performing the assay with the 
growth medium (F12 growth medium with 2% of FCS, 100 µg/mL or 100 U/mL of 
Penicillin/Streptomycin and 0.8 mg/mL of G418). After the incubation, the cells were 
washed with Hank’s buffered saline solution (HBSS) consisting of NaCl (13 mM), 
HEPES (20 mM), glucose (5.5 mM), KCl (5.4 mM), NaHCO3 (4.2 mM), CaCl2 x 2H2O 
(1.25 mM), MgSO4 (0.8 mM), MgCl2 (1 mM), KH2PO4 (0.44 mM) and Na2 PO4 (0.34 
mM) dissolved in deionized, autoclaved water. 
After the addition of 200 µL or 185 µL of HBSS per well for agonist or 
antagonist test, respectively, cells were incubated for 2 hours at 37ºC. After this 
period of time, 20 µL of the phosphodiesterase inhibitor Ro-20-1724 (4-(3-butoxy-4-
methoxybenzyl)-2-imodazolidinone), final concentration 40 µM, dissolved in HBSS, 
was added and the suspension incubated for 10 minutes. 15 µL of the test compound 
was diluted in HBSS containing 10% DMSO, to obtain the desired concentration, and 
added to the suspension. After 5 minutes of incubation, 15 µL of forskolin (final 
concentration: 10 µM), prepared with HBSS containing 10% of DMSO, were added to 
each well. Antagonists were added at the desired concentration 20 minutes before 
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adding the agonist. The final DMSO concentration was 1.9%. The suspension was 
incubated for 10 minutes after the addition of Ro-20-1724, again for 5 minutes after 
the addition of the test compound, and for another 15 minutes after adding forskolin. 
cAMP accumulation was stopped by removing the supernatant from the cell 
suspension and subsequently lyzing the cells with 500 µL of hot lysis buffer (120ºC; 4 
mM EDTA, 0.01% Triton X-100). Aliquots of 50 µL of cell suspension were 
transferred to 2.5 mL tubes, 30 µL of [3H]cAMP (3 nM) and 40 µL of cAMP-binding 
protein (50 µg per well) were added, followed by 1 hour incubation on ice. Bound and 
free radioligand were separated by rapid filtration through GF/B glass fiber filters 
using a Brandel 48-channel cell harvester (Brandel, Gaithersburg, MD). Radioactivity 
on the filters were determined in a liquid scintillation counter (TRICARB 2900TR, 
Packard/Perkin-Elmer) after 6 hours of preincubation with 3 mL of scintillation 
cocktail (LumaSafePlus, Perkin-Elmer).  





7. Data Analysis 
All data were processed with Microsoft Excel (2016) and further analysed 



























1. Compound library 1 on GPR18  
1.1. Compounds from compound library 1 did not show agonist 
activity on GPR18 
 
In order to identify new compounds that act as agonists or antagonists of 
GPR18 we performed an initial screening using the β-arrestin recruitment assays. 
The compound library tested, is a proprietary in-house library of compounds that 
have structural similarities to previously identified ligands of GPR18, and to other in-
house compounds that also showed capacity to activate or inhibit GPR18 in previous 
studies from our lab (24).  To test if these compounds can act as agonists, CHO cells 
expressing GPR18 were incubated with each compound at a concentration of 10 µM, 
for 90 minutes (Fig. 14). For the antagonist test, cells were pre-treated with each 
compound at a concentration of 10 µM, for 60 minutes, and then they were further 
incubated with 0.1 µM peptide-like agonist, a GPR18 agonist, for another 90 minutes 
(Fig. 15). The activation or inhibition was assessed by chemiluminescent output of β-
galactosidase activity. All data result from three independent experiments (N=3), 
performed in duplicate. Data represents mean ± SEM and is expressed as 
percentage of GPR18 activation, or inhibition of receptor activation, for the agonist 































































































































































































































































Figure 14: Screening of agonist activity of compound library 1 on GPR18. CHO cells expressing GPR18 
were treated with each compound at 10 µM for 90 minutes. 0.1% BSA in PBS and 0.1 µM peptide-like agonist 
were used as blank and positive control, respectively. The activation was assessed by the measurement of the 
luminescence produced and is expressed as percentage of GPR18 activation. Data represents mean ± SEM from 





Figure 15: Screening of antagonist activity of compound library 1 on GPR18. CHO cells expressing GPR18 
were pre-treated with each compound at a concentration of 10 µM, for 60 minutes, and then they were further 
incubated with 0.1 µM peptide-like agonist, a GPR18 agonist, for another 90 minutes. 0,1% BSA in PBS and 0.1 
µM peptide-like agonist were used as blank and positive control, respectively. The inhibition was assessed by the 
measurement of the luminescence produced and is expressed as percentage of inhibition of GPR18 activation. 
Data represents mean ± SEM from three independent experiments (N=3), performed in duplicate.   
 
Analysing the results of the study of the agonist activity, it is possible to 
observe that none of the compounds promoted a GPR18 activation higher than 50%. 
 
On the contrary, in the study of the antagonist activity several of compounds 
showed an inhibition of GPR18 activation higher than 50%, including compound 1, 
compound 2, compound 3, compound 4, compound 5, compound 6, compound 7, 
compound 8, compound 9, compound 13, compound 15, compound 24, compound 
25, compound 26, compound 27, compound 28, compound 29, compound 30, 
compound 31, compound 32, compound 33, compound 34, compound 35, compound 
36, compound 37, compound 38, compound 39, compound 40, compound 41 and 
compound 42. 
 
We decided to proceed with our studies with compounds that showed a 





















1.2. Compounds from compound library 1 showed to be selective for 
GPR18 
 
In the second phase of our work, we evaluated the selectivity of compounds 
from compound library 1 for GPR18, by analysing the activity of the same 
compounds on GPR55, using the same methodological approach. Therefore, once 
again, we performed agonist and antagonist tests in CHO cells expressing GPR55 by 
the procedure described above. In this case we used 2 µM LPI as a positive control. 
All data result from three independent experiments (N=3), performed in duplicate. 
Data represents mean ± SEM and is expressed as percentage of GPR55 activation, 
or inhibition of receptor activation, for agonist test or antagonist test, respectively. 
 
As can be seen from the results showed in Figure 16, none of the compounds 
activated the GPR55 more than 50%. According to Figure 17, only the compound 31 
showed a capacity to inhibit GPR55 activation higher than 50%. 
 
































































































































































































































































Figure 16: Screening of agonist activity of compound library 1 on GPR55 to study the selectivity for 
GPR18. CHO cells expressing GPR55 were treated with each compound at 10 µM for 90 minutes. 0,1% BSA in 
PBS and 2µM LPI were used as blank and positive control, respectively. The activation was assessed by the 
measurement of the luminescence produced and is expressed as percentage of GPR18 activation. Data 
































































































































































































































































Figure 17: Screening of antagonist activity of compound library 1 on GPR55 to study the selectivity for 
GPR18. CHO cells expressing GPR55 were treated with each compound at 10 µM for 60 minutes, and then they 
were further incubated with 2 LPI, a GPR55 agonist, for another 90 minutes. 0,1% BSA in PBS and 2 µM LPI 
were used as blank and positive control, respectively. The inhibition was assessed by the measurement of the 
luminescence produced and is expressed as percentage of inhibition of GPR55 activation. Data represents mean 



































1.3. Some of the compounds from compound library 1 showed 
moderate antagonist potency 
 
After the initial screening, the antagonist and agonist potencies of each 
selected compounds that showed antagonist or agonist activity, respectively, were 
evaluated. Once again, using the β-arrestin recruitment assays, the cells were 
treated with increasing concentrations of each compound, in the absence or 
presence of a known agonist, in order to obtain dose-response curves and to 
determine EC50 (μM) and IC50 (μM). All data result from three independent 
experiments (N=3), performed in duplicate. Data represents mean ± SEM and is 
expressed as EC50 (μM) or IC50 (μM) and as percentage of GPR18 activation, or 
inhibition of receptor activation, for the agonist test or antagonist test, respectively. 
 
Since none of the compounds showed agonist activity higher than 50%, we 
only evaluated antagonist activity. Despite the fact that compound 5, compound 8, 
compound 9, compound 13 and compound 15 showed an antagonist activity higher 
than 50%, we decided to prioritize our study to compounds that showed a percentage 
of inhibition of GPR18 activation not close to 50%. Table 4 summarise the IC50 (μM) 
obtained for each compound and the respective dose-response curve. From these 
results it is possible to observe that the compound 3 showed the highest antagonist 
potency, presenting a IC50  of 4x10-10 ±4x10-10 μM and a maximal inhibition of 62%, 
while the compound 34 showed the highest IC50 (34.5 ± 20.4 μM) and a maximal 
inhibition of 8%. Only compound 1, compound 3, compound 4 and compound 7 




Table 4: Evaluation of the antagonist potencies of compound library 1 on GPR18. 
Compound 
Human GPR18 
IC50 ± SEM (μM) 





12.9 ± 1.6 











IC50 ± SEM (μM) 

























6.27 ± 1.65 






IC50 ± SEM (μM) 





5.63 ± 1.19 




5.52 ± 0.896 




9.96 ± 2.92 




10.5 ± 0.716 











IC50 ± SEM (μM) 
































IC50 ± SEM (μM) 
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2. Compound library 2 on GPR18 
2.1. Only compound 57, compound 59 and compound 72 showed 
antagonist activity in the initial screening 
 
Using the same methodological approach described for the compound library 
1, we have screen a new proprietary library compound, the compound library 2. Once 
again, the first step was screening for compounds that may have an agonist or 
antagonist effect on GPR18, using β-arrestin recruitment assays. 
 
Evaluating the results of the agonist activity screening (Fig. 18), we can 
observe that some compounds led to an GPR18 activation higher than 50%, 
including compound 50, compound 53, compound 56, compound 58, compound 60, 
compound 61, compound 62, compound 63, compound 64, compound 65, compound 








































































































































































































Figure 18: Screening of agonist activity of compound library 2 on GPR18. CHO cells expressing GPR18 
were treated with each compound at 10 µM for 90 minutes. 0,1% BSA in PBS and peptide-like agonist (0.1 µM) 
were used as blank and positive control, respectively. The activation was assessed by the measurement of the 
luminescence produced and is expressed as percentage of GPR18 activation. Data represents mean ± SEM from 
three independent experiments (N=3), performed in duplicate.   
 
On the other hand, only treatment with compound 57, compound 59 and 





















































































































































































Figure 19: Screening of antagonist activity of compound library 2 on GPR18. CHO cells expressing GPR18 
were treated with each compound at 10 µM for 60 minutes. 0,1% BSA in PBS and peptide-like agonist (0.1 µM) 
were used as blank and positive control, respectively. The inhibition was assessed by the measurement of the 
luminescence produced and is expressed as percentage of inhibition of GPR18 activation. Data represents mean 
± SEM from three independent experiments (N=3), performed in duplicate.   
 
We decided to proceed with our studies with compounds that showed a 































2.2. None of the compounds from compound library 2 showed agonist 
activity on GPR55 
 
After assessing the agonist or antagonist activity of the compounds from 
compound library 2 , the next step of our work was the evaluation of the selectivity of 
these compounds for GPR18, by analysing their activity on GPR55, through β-
arrestin recruitment assays. Tests to determine the agonist and antagonist were 
performed in CHO cells expressing GPR55 as described above.  
 
As can be seen from Figure 20, none of the compounds of the compound 
library 2 led to GPR55 activation higher than 50%. 
 
However, compound 59, compound 60, compound 61, compound 67, 
compound 68, compound 71 and compound 72 showed a percentage of inhibition of 
GPR55 activation higher than 50% (Fig. 21). 
 
We decided to pursue our studies with all the compounds that showed activity 




Figure 20: Screening of agonist activity of compound library 2 on GPR55 to study the selectivity for 
GPR18. CHO cells expressing GPR55 were treated with each compound at 10 µM for 90 minutes. Was used 
PBS+0,1% of BSA and LPI (2µM) as blank and positive control, respectively. The activation was assessed by the 
measurement of the luminescence produced and is expressed as percentage of GPR18 activation. Data 





Figure 21: Screening of antagonist activity of compound library 2 on GPR55 to study the selectivity for 
GPR18. CHO cells expressing GPR55 were treated with each compound at 10 µM for 60 minutes. 0,1% BSA in 
PBS and LPI (2 µM) as blank and positive control, respectively. The inhibition was assessed by the measurement 
of the luminescence produced and is expressed as percentage of inhibition of GPR55 activation. Data represents 



































2.3. The compound 56 showed the highest agonist potency on GPR18 
 
Similarly to what was performed for compound library 1, the antagonist and 
agonist potencies of the compounds from compound library 2 that showed antagonist 
or agonist activity, respectively, were evaluated. So, using β-arrestin recruitment 
assays once again, the cells were treated with increasing concentrations of each 
compound, in the absence or presence of a known agonist, in order to obtain a dose-
response curves and to determine EC50 (μM) and IC50 (μM).  
 
Even though the compounds 71 and 72 did not show activation of GPR18, a 
curve-dose response was performed to confirm their lack of activity. As expected, the 
agonist activity of these compounds was not significant.  
 
Table 5 summarizes the EC50 (μM) obtained for each compound and the 
respective dose-curve response.  Analysing these results and comparing the EC50 
and the percentage of maximal activation, it is possible to observe that compound 56, 
compound 60, compound 61, compound 65 and compound 69 are the compounds 
that revealed the highest potency with EC50 of 0.0302 ± 0.004 μM, 0.219 ± 0.039 μM, 
0.113 ± 0.003 μM, 0.0679 ± 0.018 μM and of 3.60 ± 0.19 μM, respectively. The 
compound that conjugated the lowest EC50 and the highest percentage of maximal 
activation was compound 56, showing the best agonist potency (EC50 = 0.0302 ± 
0.004 μM and 107% of maximal activation). Only the compound 51 and the 
compound 58 showed a maximal activation lower than 50% (40% and 42% of 
maximal activation, respectively).   
 
 




EC50 ± SEM (μM) 





1.1 ± 1.92 





1.65 ± 1.10 







EC50 ± SEM (μM) 






0.0302 ± 0.004 





1.68 ± 0.28 





0.219 ± 0.039 





0.113 ± 0.003 





0.063 ± 0.001 







EC50 ± SEM (μM) 






4.02 ± 0.48 





0.328 ± 0.027 
(66 % of maximal activation) 




0.0679 ± 0.018 





0.285 ± 0.089 





1.66 ± 0.13 







EC50 ± SEM (μM) 






3.60 ± 0.19 





0.801 ± 0.220 





7.73 ± 1.41 





 Table 6 summarizes the IC50 (μM) obtained for each compound and the 
respective dose-curve response. In the screening study, compound 57, compound 59 
and compound 72 showed antagonist activity. Nevertheless, as can be noticed from 
results presented in Table 6, the assessment of their antagonist potencies did not 
show any significant inhibition, neither low IC50 values, with IC50 values of 1.70 ± 0.59 
μM, 2.03 ± 1.19 μM and 1.91 ± 0.00 μM, and with percentages of maximal inhibition 




















IC50 ± SEM (μM) 





1.70 ± 0.59 




2.03 ± 1.19 




1.91 ± 0.00 























2.4. The antagonist potency on GPR55 of compound 61, compound 68, 
compound 71 and compound 72 was not significant 
 
Since none of the compounds showed agonist activity on GPR55, we just 
evaluated the antagonist potency of the compounds on this receptor. For that, using 
β-arrestin recruitment assays, the cells were treated with increasing concentrations of 
each compound, in the presence of a known agonist, and the dose-response curve 
and the IC50 (μM) were obtained. All data result from three independent experiments 
(N=3), performed in duplicate. Data represents mean ± SEM and is expressed as 
IC50 (μM) and as percentage of GPR55 inhibition of receptor activation, respectively. 
 
Although compound 59 and 67 had shown antagonist activity, it was not 
possible to calculate IC50 because there was not enough volume of these compounds 
to perform the assay.  
 
In the case of compound 60, as the percentage of inhibition of GPR55 
activation demonstrated was not striking, the potency evaluation of the other 
compounds was prioritized.  
 
Table 7 summarizes the IC50 (μM) obtained for each compound and the 
respective dose-curve response. The results shown in this table indicate that the 
compounds did not have relevant antagonist potency on GPR55. The IC50 and the 
values of maximal inhibition were not significant, with IC50 values of 6.65 ± 0.13 μM, 
9.44 ± 0.39 μM, 22.1± 9.6 μM and 9.92± 1.89 μM, and values of maximal inhibition of 
10%, 55%, 19% and 20% for compound 61, compound 68, compound 71 and 
compound 72, respectively. The compound 68 was the only compound that showed 

























Table 7: Evaluation of the antagonist potencies of compound library 2 on GPR55. 
Compound 
Human GPR55 
IC50 ± SEM (μM) 
(% of inhibition of LPI activation) Curve 
Compound 
61 
6.65 ± 0.13 




9.44 ± 0.39 




22.1± 9.6   




9.92± 1.89   













3. Compound library 3 on CB2 
3.1. None of the compounds studied showed antagonist activity on 
CB2 
To identify new compounds that can bind to CB2 receptor, we performed an 
initial screening, using radioligand binding assays. The compound library tested is a 
proprietary in-house library of compounds that have structural similarities to 
previously identified ligands of CB2 and to other in-house compounds that also 
showed capacity to bind to CB2 in previous studies from our lab. Indeed, previously 
we identified several compounds from compound library 3 that had the capacity of 
binding to CB2. We decided to proceed the studies with the compounds that showed 
a percentage of inhibition of radioligand binding at 10 μM higher than 50%, including 
compound 73, compound 74, compound 75, compound 76, compound 77, compound 
78, compound 79 and compound 80.  
 
The following step was the assessment of the agonist or antagonist activity of 
the compounds from compound library 3 that had shown to be able to bind to the 
receptor in the previous assay, using cAMP accumulation assays. For that, CHO 
cells expressing CB2 were treated with 10 µM of each compound and incubated with 
it for 5 minutes. The controls used for both tests were 10% DMSO in HBSS as blank, 
1 µM CP55,940 with 10 µM forskolin as positive control in the agonist test, and 10 
µM forskolin as positive control in the antagonist test. The amount of cAMP produced 
was assessed by the determination of radioactivity present in each well. All data 
result from three independent experiments (N=3), performed in duplicate. Data 
represents mean ± SEM and is expressed as percentage of receptor activation or 
percentage of inhibition of receptor activation for agonist or antagonist test, 
respectively. 
 
Examining the results shown in Figure 22B), it is possible to observe that none 
of the compounds showed antagonist activity on CB2, since inhibition of receptor 
activation was lower than 50% for all the compounds tested. Contrary to the 
antagonist activity study, in the agonist activity study (Fig. 22A)) most compounds 
showed an activation higher than 50%, including compound 73, compound 74, 
























Figure 22: Screening of agonist (A) and antagonist (B) activity of compound library 3 on CB2. For the 
agonist test, the CHO cells expressing CB2 were incubated with 40 µM Ro-20-1724, 10 µM of each compound 
and 10 µM forskolin, added at different times in this order. For the antagonist test, the cells were incubated with 
40 µM Ro-20-1724, with 3nM CP55.940, 10 µM of each compound,  and 10 µM forskolin, added at different times 
in this order. The controls used for both tests were 10% DMSO in HBSS as blank, 1 µM CP55.940 with 10 µM 
forskolin as positive control at agonist test, and 10 µM forskolin as positive control at antagonist test. The 
radioactivity was determined in order to assess the amount of cAMP produced. All data result from three 
independent experiments (N=3), performed in duplicate. Data represents mean ± SEM and is expressed as 






























3.2. The compounds tested showed high potency on CB2 
After the initial screening, and since none of the compounds showed 
antagonist activity on CB2, we just evaluated the agonist potency of the compounds 
on this receptor. Therefore, using cAMP accumulation assays, cells were treated with 
increasing concentrations of each compound, in order to obtain a dose-response 
curve and to determine the Ki (µM). All data result from three independent 
experiments (N=3), performed in duplicate. Data represents mean ± SEM and is 
expressed as Ki (µM) and as percentage of maximal inhibition of radioligand binding 
at 10 µM. 
 
Table 8 summarizes the results of the agonist potencies of compound library 3 
on CB2. As it is possible to observe from this table, all the compounds of compound 
library 3 tested were potent on CB2, having shown a maximal inhibition near to 100% 
and a Ki lower than 1 µM, with Ki values of 0.498 ± 0.176 µM, 0.237 ± 0.006 µM, 
0.536 ± 0.058 µM, 0.339 ± 0.061 µM, 0.338 ± 0.146, 0.628 ± 0.07 µM and 0.716 ± 
0.001 µM, and percentages of maximal inhibition of 98%, 98%, 96%, 99%, 99%, 97% 
and 99% for compound 73, compound 74, compound 75, compound 76, compound 
77, compound 78 and compound 79, respectively. The compounds that conjugated 
the highest maximal inhibition with the lowest Ki were the compound 76 and 74. 
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3.3. The compounds 74, 75 and 78 did not show specificity for CB2 
 
To evaluate the selectivity of these compounds for CB2, we studied the activity 
of the same compounds on CB1. 
 
Therefore, the first step was performing a screening, using radioligand binding 
assays. In order to test the binding capacity of the compounds from compound library 
3, a preparation containing the receptor of interest was incubated with 0.1 nM of 
radioligand and with 10 µM of each compound, for 120 minutes. DMSO was used to 
assess the Total Binding of radioligand and 10 µM unlabeled CP 55.940 was used to 
determine the Non-Specific Binding of radioligand. The inhibition of radioligand 
binding was determined by measuring the radioactivity present in each well and data 
was expressed as percentage of inhibition of radioligand binding at 10 Μ. All data 
result from three independent experiments (N=3), performed in duplicate. Data 
represents mean ± SEM and is expressed as percentage of inhibition of radioligand 
binding at 10 μM. 
 
Since none of the compounds showed antagonist activity on CB2, the 
selectivity study was performed with the compounds that showed agonist activity on 
this receptor.  
 
So, in the next step, we performed the agonist test and the evaluation of the 
respective potencies, using cAMP accumulation assays. The procedures and the 
controls used were the same that the ones used for CB2 assays. All data result from 
three independent experiments (N=3), performed in duplicate. Data from the agonist 
screening is not shown. Data from the potency evaluation represents mean ± SEM 
and is expressed as Ki (µM) and as percentage of maximal inhibition of radioligand 
binding at 10 µM. 
 
Table 9 summarizes the results of the screening and the evaluation of the 
agonist potencies of compound library 3 on CB1. The results showed that the 
compounds 73, 76 and 79 did not have significant binding capacity to the CB1 
receptor, demonstrating a percentage of inhibition of radioligand binding lower than 
or close to 50% (35%, 47% and 53%, respectively). Compound 74, compound 75, 
compound 77 and compound 78 showed to act as agonists on CB1 (data not shown). 
As can also be seen from Table 9, the compounds 74, 75 and 78 were not potent 
agonists of CB1, besides showing a high percentage of maximum inhibition (92%, 
89% and 93%, respectively), they showed a high Ki (4.07 ± 1.36 µM, 7.13 ± 1.68 µM, 
and 8.66 ± 3.82 µM, respectively). Compound 77 showed a low percentage of 
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Discussion, Conclusions and Future Perspectives 
GPCR family comprises more than 1000 receptors, involved in the control of 
several physiologic and pathophysiologic processes, including cancer, hypertension, 
abnormal bone development, thyroid dysfunction, and others. The complexity of its 
activation and signalling pathways, including heterodimerization, binding to several 
and distinct effector proteins and the possibility of allosteric modulation, raise several 
obstacles and challenges in drug discovery process. Though, the number of drugs 
targeting these receptors has been increasing, counting with more than 475 FDA 
approved drugs, acting at 108 different GPCRs, including drugs for the treatment of 
T2D, depression, hypertension, PD, and others (2,8,10).  
 
Given the importance of this class of receptors, our work aimed to identify 
compounds that can be able to activate or inhibit four specific GPCRs, CB1, CB2, 
GPR55 or GPR18, and, consequently, could be used as therapeutic approaches in 
several pathologies, such as those mentioned above. In previous studies, our lab 
described several ligands for CB1, CB2, GPR55 and GPR18, and identified new 
compounds, from an in-house library, that were able to activate/inhibit these 
receptors. So, using the molecular structures of this recently identified hits as a 
starting point, we tested new compounds, also belonging to our in-house library, in 
order to search for novel molecules with therapeutic potential. Therefore, the first 
step was the screening of two different libraries, followed by selectivity studies and 
evaluation of the potency of the compounds. 
 
CB1 and CB2 are two cannabinoid receptors, mediating the effects of Δ9-THC, 
AEA and 2-AG. CB1 is one of the most abundant GPCRs in the brain, being involved 
in psychoactive effects, which limits its use as a therapeutic target. On the other 
hand, CB2 is highly distributed in peripheral organs with immune function. Since CB2 
ligands do not appear to produce psychotropic effects, this receptor is considered a 
promising therapeutic for the treatment of diverse pathologies, including painful 
conditions, neuroinflammatory or neurodegenerative disorders, such as PD or MS, 
and other inflammatory disorders like atherosclerosis (2,12,16, 17,19).  
 
GPR55 and GPR18 are two of the 140 GPCRs classified as orphan receptors. 
GPR55 is highly expressed in the CNS and in peripheral tissues such as endothelial 
cells, bone, lymphocytes, and in other systems, and LPI and 2-AGPI are ligands for 
this receptor. More recently, a correlation between GPR55 expression levels and the 
rate of cancer cells proliferation, was established. GPR55 may be a potential target 
to several disorders, including diabetes, obesity, cancer, osteoporosis and 
Parkinson’s disease. In its turn, GPR18 may modulate the immune responses in 
acute inflammation situations. NAGly and RvD2 are considered endogenous agonists 
for GPR18, while amauromine is the only GPR18 antagonist described. There are 
evidences that places this receptor as a target for the treatment of several 
inflammatory diseases, osteoporosis, cancer and obesity (2,3,12,18,22,23,25). 
 
In order to identify compounds that are be able to modulate the activity of these 
receptors, as previously mentioned, the first step was the screening of these 





The agonist and antagonist activity of two distinct series of compounds 
(compound library 1 and 2), for GPR18 were screened, using the β-arrestin 
recruitment assays. For the compound library 1, 42 compounds were tested. Our 
results show that none of the compounds showed agonist activity, while 30 
compounds exhibited capacity for inhibit GPR18 activity (Fig. 23). On the other hand, 
for compound library 2, 30 compounds were tested. The analysis of these results 
revealed that 13 of these compounds could activate GPR18, while only three of them 
showed antagonist activity (Fig. 24). We chose to continue the studies with the 
compounds that showed a percentage of activation of GPR18 or inhibition of receptor 
activation higher than 50%. Unfortunately, we were not able to amauromine, a 
GPR18 antagonist, as a negative control, in order to compare the activity between 
the different compounds, and this well-established antagonist. 
 
The following step was the evaluation of the selectivity of these compounds for 
GPR18, performing a screening with the same compounds and analysing their 
activity on GPR55. Thus, the same methodological approach was used, and the 
agonist and antagonist tests were performed. Were studied the selectivity of the 42 
compounds of compound library 1. The results did not show any compound with 
agonist activity on GPR55 and only one compound (compound 31) showed activation 
capacity of GPR55 slightly higher than 50%, not showing selectivity for GPR18 (Fig. 
23). All the other compounds showed to be GPR18 selective. For compound library 
2, 30 compounds were tested, and the results show that none of them activate 
GPR55, however, seven compounds were able to act as antagonist on GPR55 (Fig. 
24). It is possible to conclude that compound 72 and compound 59 are not selective 
antagonists for GPR18, and compound 60 and compound 61, besides not being 
GPR18 selective, have opposite activities on the receptors, acting as agonists in 
GPR18 and as antagonists in GPR55. Further studies proceeded with all the 
compounds, selective or not for GPR18. Similarly to the screening for GPR18, a 






























Figure 23:Representation of the number of compounds from compound library 1 vs type of modulation 
activity on GPR18 and GPR55. None of the compounds from this library showed to act as agonists on GPR18 or on 
GPR55. Three compounds revealed antagonist activity on GPR18, although one of these compounds also act as 























Finally, the agonist and antagonist potencies of the compounds on GPR18 were 
evaluated, in order to obtain a dose-response curves and to determine EC50 (μM) 
and IC50 (μM) for each compound. Thereby, using once again β-arrestin recruitment 
assays, cells were treated with increasing concentrations of each compound, in the 
absence or presence of a known agonist. Analysing the results for compound library 
1, it is possible to observe that compound 3 was the compound that showed the 
higher inhibitory potency, while compound 34 showed to be the less potent 
compound. Only compound 1, compound 3, compound 4 and compound 7 showed a 
percentage of maximal inhibition higher than 50%. However, it would be interesting to 
perform studies with more and lower concentrations of compound 1, compound 3, 
compound 4 and compound 7, in order to obtain a better defined dose-response 
curve and analysing the potency more accurately. The compounds from compound 
library 2 with agonist activity seem to be more promising, with more compounds 
showing high potencies. The results of agonist potency evaluation show that 
compound 56, compound 60, compound 61, compound 65 and compound 69 are the 
compounds that revealed the highest potency, being compound 56 the one that 
conjugate the lowest EC50 and the highest percentage of maximal activation. Though, 
the study of antagonist potencies showed that compound 57, 59 and 72 are not 
potent antagonists.  
 
The antagonist potency on GPR55 was also evaluated for compound library 2 
that showed antagonist activity on this receptor, however, none of the compounds 
showed to be potent antagonists.  
 
Examining transversely the results obtained with compound library 1 and 2, of all 















Figure 24:  Representation of the number of compounds from compound library 2 vs type of modulation 
activity on GPR18 and GPR55. Thirteen of the compounds from this library activated GPR18, but only ten 
compounds were able to selectively activate GPR18, while the other three also act as GPR55 antagonists. Three 
of the compounds showed to be able to inhibit GPR18, however, only one of these compounds inhibit in a 











Figure 25: Representation of the number of compounds from compound library 3 vs type of modulation 
activity on CB2 and CB1. None of the compounds showed to have antagonist activity on CB2, while only three 
compounds revealed to selectively activate CB2. 
molecule was compound 56, presenting selectivity for GPR18 and a high potency. 
So, compound 56 should be a focus of more and deeper studies and its’ molecular 
structure should be a starting point for the development of other compounds. 
 
Similarly of what was performed for GPR18, to study new compounds targeting 
CB2 that may have therapeutic potential, the first step was the screening of a series 
of compounds called compound library 3. Using radioligand binding assays, previous 
studies of our lab identified 8 compounds with capacity to bind to CB2. So, the next 
step was the screening of the agonist or antagonist activity of these compounds, 
using cAMP accumulation assays. The screening results revealed that none of the 
compounds from compound library 3 tested had antagonist activity on CB2, while 
seven of them presented agonist activity (Fig. 25). We decided to continue the 
studies with the compounds that led to a receptor activation higher than 50%. 
 
The second step was the evaluation of the agonist potency of these seven 
compounds, using cAMP accumulation assays once again. Analysing the results, it 
was possible to observe that all the compounds from compound library 3 tested were 
potent on CB2, having shown a maximal inhibition near to 100% and a Ki lower than 
1 µM, and the compounds that showed, simultaneously, the highest maximal 
inhibition and the lowest Ki values were compound 76 and compound 74.  
 
Lastly, the selectivity of compound library 3 for CB2 was assessed by studying 
their binding capacity to CB1, followed by the screening of agonist activity and the 
potency study of these compounds, using radioligand binding assays and cAMP 
accumulation assays, respectively. The results showed that compound 73, 
compound 76 and compound 79 did not bind to CB1, being selective for CB2, while 
four compounds showed to act as non-potent agonists on CB1, not showing 













Analysing the results obtain with compound library 3, compound 76 showed to be 
the compound with the best potential to agonizing CB2, being selective and a potent 




For all screenings with compound library 3, it would be interesting to use a 
negative control, in order to compare the activity between the different compounds. 
The antagonist test on CB1 should also be performed, but because of time constrain 
that was not possible to do. 
 
The fact that the chemical structures of these compounds is under confidential 
agreement, did not make it possible to establish a relation between the molecular 
modifications in each structure and the effect on the receptors’ activity, in order to 
identify important functional groups in this modulation. Possibly, receptor selectivity 
or agonist/antagonist activity are achieved by specific functional groups. It would be 
interesting to see if compounds 76 and 74 from compound library 3, have similar 
molecular structures since they are both potent agonists on CB2. It would also be 
interesting to compare compound 56 molecular structure with NAGly and RvD2 to 
study eventual molecular similarities. 
 
At this point, a lot of questions need to be answered and more studies need to be 
performed. As mentioned before, the identification of functional groups involved in 
the receptors’ activity is essential. It would also be interesting to analyse changes in 
receptors’ gene expression in the presence of these compounds, which signalling 
pathway are being activated, as well as the conformational state of the receptor ideal 
to the binding of the compound. More selectivity studies, using other cannabinoid 
receptor-like GPCR, such as GPR119, and also cannabinoid receptors, should be 
performed, in order to achieve more selective therapies.  
 
In the past few years, we have been observing a remarkable progress in GPRC 
drug discovery, and the direction that the future research is taking in this area looks 
promising. The advances in crystallography, molecular modelling, protein 
engineering and biophysical techniques, allowed the discovery of compounds 
targeting GPCRs and their structure-based optimization. The future of the 
development of novel therapeutic approaches targeting GPCRs, including CB1, CB2, 
GPR18 and GPR55, points towards the improvement and innovation of drug design 
techniques, allowing more accurate studies of molecular structures and of signalling 
dynamic of the receptors. Biased ligands, allosteric modulators and monoclonal 
antibodies are becoming an attractive therapeutic strategy, aiming the development 
of more selective and effective ligands (2,8). 
 
In summary, our preliminary results demonstrate that, within the set of 
compounds tested, compound 56 is the most promising antagonist for GPR18, while 
compound 76 seem to be a promising molecule targeting CB2, acting as a potent 
agonist. In the future, more studies need to be done to understand how these 
compounds modulate these receptors’ activity and to optimize their activity, with the 
goal of developing new molecules that could be used as a therapeutic approach to 
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